Rapid response: Updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines

On November 16, 2021, NACI reviewed the recent evidence on myocarditis/pericarditis following COVID-19 vaccination including data from Canada, Israel, the United States (US), France, and Nordic countries (Denmark, Finland, Norway, Sweden). NACI discussed this recent evidence while considering data on the epidemiology of COVID-19 infection, safety, immunogenicity, efficacy/effectiveness of COVID-19 vaccines as well as ethics, equity, feasibility, and acceptability.

Following a comprehensive review, NACI updated and approved its recommendations on the use of the COVID-19 vaccines authorized for use among individuals aged 12 years and older in the context of myocarditis and pericarditis following vaccination on November 16, 2021. NACI continues to review the evidence on the use of COVID-19 vaccines. Recommendations on revaccination of individuals aged 12 years and older with a history of myocarditis/pericarditis following a previous dose of an mRNA COVID-19 vaccine is not covered in this document but will be addressed in future updates.